Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer

Immunotherapy has been found to be efficient in a variety of cancers and, therefore, may be a promising strategy for breast cancer (BC), particularly due to the limited therapeutic options currently available for triple-negative BC (TNBC). However, heterogeneity of tumor mutation burden (TMB), immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junnan, Bao, Hua, Wu, Xue, Wang, Xiaonan, Shao, Yang W., Sun, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540262/
https://www.ncbi.nlm.nih.gov/pubmed/31289516
http://dx.doi.org/10.3892/ol.2019.10287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540262/
https://www.ncbi.nlm.nih.gov/pubmed/31289516
http://dx.doi.org/10.3892/ol.2019.10287

Ejemplares similares